Infectious disorders drug targets最新文献

{"title":"Diagnostic Stewardship in Clinical Microbiology: An Indispensable Component of Patient Care.","authors":"Lipika Singhal, Parakriti Gupta, Varsha Gupta","doi":"10.2174/0118715265294425240607110713","DOIUrl":"10.2174/0118715265294425240607110713","url":null,"abstract":"<p><p>Emerging infectious diseases and increasing resistance to available antimicrobials are mapping the evolution of clinical microbiology and escalating the nature of undertakings required. Rapid diagnosis has become the need of the hour, which can affect diagnostic algorithms and therapeutic decisions simultaneously. Subsequently, the concept of 'diagnostic stewardship' was introduced into clinical practice for coherent implementation of available diagnostic modalities to ensure that these new rapid diagnostic technologies are conserved, rather than consumed as part of health care resources, with a view to improve the patient care and reduce Turnaround Time (TAT) and treatment expense. The present study highlights the requisite of diagnostic stewardship and outlines the infectious disease diagnostic modalities that can assist in its successful implementation. Diagnostic stewardship promotes precise, timely diagnostics, from the initial specimen collection and identification to reporting with appropriate TAT, so as to enable timely management of the patient. The main aim of diagnostic stewardship is to optimize the right choice of diagnostic test for the right patient to attain clinically significant reports with the least possible TAT for timely management and the least expected adverse effects for the patient, community, and the healthcare system. This underlines the requisite of a multifaceted approach to make technological advancements effective and successful for implementation as a part of diagnostic stewardship for the best patient care.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":"e030724231543"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant Nutraceuticals: Their Adjunct Role in the Management of COVID-19 Infections and Post-COVID Syndrome.","authors":"Naheed Mojgani, Maryam Dadar, Youcef Shahali, Jesus Simal-Gandara, Prashant Kumar, Sumel Ashique, Mithun Bhowmick, Himanshu Kumar","doi":"10.2174/0118715265320091241017161919","DOIUrl":"https://doi.org/10.2174/0118715265320091241017161919","url":null,"abstract":"<p><p>The COVID-19 epidemic in recent years has been produced by various coronavirus strains that nearly destroyed world health policies and economics. Emerging viral strains exac-erbated the pandemic. Huge investments have been made in preventative vaccines to combat the disease, but the genetic instability of these viruses has hampered their usefulness. However, in addition to traditional therapeutic approaches, nutraceuticals have been considered effica-cious in preventing and or treating COVID-19 and post-COVID syndrome. In this context, nutraceuticals such as vitamins or dietary supplements including multiple vitamins and miner-als and propolis have been widely studied for their significant impact on viral respiratory dis-eases like SARS-CoV-2 and COVID-19. Some of these nutraceuticals having antioxidant, anti-inflammatory, and immune-modulatory properties have been highly recommended for use as an adjunct option to moderate the adverse effects associated with the COVID-19 pandemic. In this review, we intend to present the recent understanding and converse scientific implications for the use of nutraceutical antioxidants such as vitamins, minerals, probiotics, and polyphenols like bee propolis, in the management of viral respiratory diseases and post-COVID-19 syn-drome. Future challenges and limitations regarding the use and bioavailability of these ingre-dients, and dose-response studies are further emphasized.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142934320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of Phytochemicals as Anti-biofilm Agents Against Pathogenic Bacteria: Their Potential and Challenges.","authors":"Debolina Banerjee, Poulomi Biswas, Kamalika Mazumder, Sangita Palai, Chowdhury Mobaswar Hossain, Sanmoy Karmakar, Kaushik Biswas","doi":"10.2174/0118715265324950241204182204","DOIUrl":"https://doi.org/10.2174/0118715265324950241204182204","url":null,"abstract":"<p><p>Multicellular surface-attached populations of bacteria embedded in the extracellular matrix are known as biofilms. Bacteria generally preferred to grow as biofilms. Quorum sensing (QS), detection of density of cell population through gene regulation, has been found to play an important role in the production of biofilms. Biofilm formation can increase the severity of infections that can lead to morbidity or mortality. Bacteria living within biofilms have a higher pattern of adaptive resistance to antibiotics. Antibiotic resistance is a barrier in the treatment of biofilmsinduced acute to chronic infections such as post-surgery infections, surgery-associated wound infections, endocarditis, joint infections, burn-related wound infections occurred, ventilator-associated pneumonia, etc. So it is urgent to discover or find out potent new drugs in fight against infectious diseases such as biofilms-associated infections. Medicinal plants or herbs are a rich source for fighting with biofilms-mediated infections. Phytochemicals have exhibited significant effects in the prevention of biofilms formation against different bacteria that are causing infections. Purified compounds such as berberine, tetrandrine, embelin, xanthorrhizol, bakuchiol, etc., exhibited promising biofilm inhibition actions against different pathogenic bacteria. Plant extracts that contain several phytochemicals are evaluated for its biofilm's inhibition property, and have shown significant potential in biofilm formation. Antibiofilm agents act by distinct mechanisms such as inhibiting the adherence of biofilms in a surface, preventing the biofilm formations, disrupting the matured biofilms, etc. This study is intended to reiterate about possibilities of plant extracts and purified compounds in the treatment of the prevention of bacterial biofilms-related infections.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142934321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Potential Use of Withania somnifera in Leprosy and Lepra Reactions: A Molecular Docking Approach.","authors":"Pugazhenthan Thangaraju, Thiyagarajan Saraswathy, Hemasri Velmurugan, Sajitha Venkatesan, Sree Sudha Ty, Pankaj Maheshwari, Ray Radha Sargunam, Alagesan Srinivasan, Eswaran Thangaraju, Tamilselvan Thangaraju","doi":"10.2174/0118715265296476241018050329","DOIUrl":"https://doi.org/10.2174/0118715265296476241018050329","url":null,"abstract":"<p><strong>Introduction: </strong>Withania somnifera (Ashwagandha) is a traditional herb that is cur-rently commercially available for treating a variety of illnesses. By evaluating and verifying docking affinity scores, it is possible to explore the potential of the plant for treating leprosy and lepra-reaction as off-label use.</p><p><strong>Methods: </strong>The sitoindosides were used as ligands along with thalidomide in docking against targets, such as M. leprae, TNF-Alpha, and Interleukin-6 in order to determine the potential for inhibitory concentration and docking affinity.</p><p><strong>Results: </strong>According to the study, good binding energy values varied from -7 to -11 Kcal/mol. Sitoindoside IX had the highest binding affinity and important binding interactions, such as hydrogen bonding, when compared to Thalidomide and Sitoindoside X against all three re-ceptors.</p><p><strong>Conclusion: </strong>The present study confirmed that the Sitoindoside IX and X are a better fit for treating patients with leprosy. These findings are highly intriguing and suggest that this herb should be investigated further to validate these findings in leprosy.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142934322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herbal Medicine for the Management of Wounds: A Systematic Review of Clinical Studies.","authors":"Lokman Ali Ahmed, Arshadul Hussain, Pervej Alom Barbhuiya, Samsuj Zaman, Abdul Mannaf Laskar, Manash Pratim Pathak, Partha Pratim Dutta, Saikat Sen","doi":"10.2174/0118715265320593241007095952","DOIUrl":"https://doi.org/10.2174/0118715265320593241007095952","url":null,"abstract":"<p><strong>Background: </strong>Cuts and wounds are unfortunate yet inevitable events. Traditional remedies have historically harnessed various plants for wound healing, undergoing clinical and pre-clinical scrutiny. Hence, this systematic review focuses on clinically researched herbal formulations for wound healing.</p><p><strong>Methodology: </strong>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, databases like Google Scholar, Web of Science, PubMed, Scopus, J-gate, and Ayush Research Portal were meticulously searched for clinical trials in-volving wound-targeting herbal formulations, alongside a comprehensive hunt for preclini-cal plant data.</p><p><strong>Results: </strong>Among 623 screened documents, 26 published clinical trials spotlighting herbal wound healing formulations were identified. All studies showcased significant wound heal-ing progress, with some surpassing standard betadine treatment. Only one study reported an adverse effect. Within the 26 formulations, 45 distinct plant species were employed, with 35 exhibiting wound healing attributes like antimicrobial, anti-inflammatory, and antioxidant activities scientifically. Enhanced collagen content, stabilized fibers, activated fibroblast cells, increased total protein, elevated growth factors, hydroxyproline, hexosamine, and tis-sue protein demonstrate the efficacy of plants, such as Hypericum perforatum, Centella asi-atica, and Calendula officinalis in wound healing.</p><p><strong>Conclusion: </strong>The findings of the current study indicated that medicinal plants are effective and safe agents for the treatment of wounds, though larger, well-designed trials are needed for definitive role confirmation.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142934325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro Anti-biofilm and Anti-adhesion Effects of Lactic Acid Bacteria- derived Biosurfactants against Streptococcus mutans.","authors":"Maryam Pourhajibagher, Abbas Bahador","doi":"10.2174/0118715265336536241014072854","DOIUrl":"https://doi.org/10.2174/0118715265336536241014072854","url":null,"abstract":"<p><strong>Introduction: </strong>Biosurfactants are naturally occurring compounds with various ap-plications, biodegradable, non-toxic, and effective in different conditions. This study fo-cuses on the extraction and evaluation of biosurfactants produced by five strains of lactic acid bacteria [LAB] for their potential to inhibit biofilm formation and adhesion by Strep-tococcus mutans.</p><p><strong>Methods: </strong>The strains of LAB-producing biosurfactants such as Lactobacillus salivarius, L. acidophilus, L. plantarum, L. casei, and L. rhamnosus were confirmed by the hemolysis test. The presence of biosurfactants derived from LAB strains and their molecular compo-sition were confirmed, and their cellular toxicity, minimum inhibitory concentration [MIC], and minimum bactericidal concentration [MBC] were investigated. Ultimately, the anti-biofilm and anti-adhesive activities of LAB-derived biosurfactants against S. mutans were determined. Eventually, the effect of biosurfactants on the changes in gene expression associated with biofilm formation of S. mutans was assessed. All the LAB strains used in this study were biosurfactant producers. The LAB-derived bi-osurfactants exhibited no cytotoxicity towards the human gingival fibroblast [HGF] cell line. According to the results, the lowest and highest MIC values were observed in the biosurfactants derived from L. rhamnosus and L. plantarum at 0.78 mg/mL and 6.25 mg/mL, respectively. The MBC values for the biosurfactants derived from L. rhamnosus, L. casei, L. salivarius, L. acidophilus, and L. plantarum were 3.12, 3.12, 6.25, 12.5, and 12.5 mg/mL, respectively. The LAB-derived biosurfactants at MBC concentrations exhib-ited significant inhibitory effects on biofilm formation and adhesion of S. mutans [P<0.05]. The highest anti-biofilm and anti-adhesion activities were attributed to the biosurfactants derived from L. plantarum, which were not significantly different from the 0.2% chlorhex-idine as a positive control group [P>0.05]. Moreover, all biosurfactants could significantly decrease the gene expression level of gtfB [P>0.05].</p><p><strong>Results: </strong>The study found that LAB-derived biosurfactants exhibit significant anti-adhesion and anti-biofilm activities against S. mutans without any observed cellular toxicity towards HGF cells.</p><p><strong>Conclusion: </strong>These promising bioactive compounds can be utilized as natural antimicrobial agents and biofilm inhibitors to prevent microbial biofilm formation and adhesion in vari-ous dental applications, offering a safe and effective alternative for controlling dental bio-films and improving oral health outcomes.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensification of Invasive Fungal Infections and Exploration of Effective Antifungal Drug Delivery Formulations: A Detailed Review.","authors":"Shrikant Mahesh Sharma, Rupali Sharma, Pankaj Chandrateya","doi":"10.2174/0118715265317733241021190116","DOIUrl":"https://doi.org/10.2174/0118715265317733241021190116","url":null,"abstract":"<p><p>Invasive fungal infections (IFIs) pose a significant global health threat, particularly among immunocompromised individuals. These infections can lead to severe illness and death, placing a significant financial burden on healthcare systems. Fungi were not previously considered a substantial risk to human health, but this perception changed with the rise of the HIV epidemic. The emergence of drug-resistant fungal strains further complicates the man-agement of these infections, highlighting the urgent need for effective antifungal therapies. Addressing this challenge requires innovative approaches and antifungal drug delivery for-mulations as promising strategies. This article explores the role of effective antifungal drug delivery formulations in combating the rise of IFIs. These formulations, ranging from lipid-based systems like liposomes and lipid emulsions to polymeric nanoparticles and micropar-ticles, offer several advantages over conventional drug delivery methods. Optimizing these formulations may improve drug efficacy, reduce the risk of drug resistance, and enhance pa-tient outcomes. Furthermore, advancements in nanotechnology and targeted drug delivery systems hold promise in overcoming existing limitations and expanding the scope of antifun-gal therapies.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Severity of COVID-19 in Systemic Lupus Erythematosus Patient.","authors":"Kishor R Danao, Vijayshri V Rokde, Ujwala N Mahajan","doi":"10.2174/0118715265326851241115072224","DOIUrl":"https://doi.org/10.2174/0118715265326851241115072224","url":null,"abstract":"<p><p>As of early October 2020, the COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, resulted in approximately 35 million cases and one million fatalities worldwide. Systemic lupus erythematosus (SLE) is an autoimmune disease marked by the generation of pathogenic autoantibodies and a lack of tolerance to nuclear self-antigens. Hypocomple-mentemia, or an abnormal blood complement deficit, is a reliable predictor of infection in SLE patients. Moreover, it has been found that immunoglobulin (Ig), particularly IgG and IgM, is lowered in SLE patients, which may be a factor in their heightened susceptibility to infection. Bloodstream autoantibodies, lymphopenia, aberrant T cells, proinflammatory cytokines, and impaired regulatory systems all lead to an immune response that is aberrant in lupus patients. SLE patients exhibit impaired CD8 T cell responses, including abnormal phagocytosis and chemotaxis. Recent study has shown that COVID-19 infections significantly boost type I inter-feron responses. Patients with SLE and Covid-19 infection typically get immune-suppressing drugs viz corticosteroids, Janus kinase inhibitors (JAK), and tocilizumab, which improve their immune systems and diminution susceptible to Covid-19 infections.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Potential of Emodin: A Mini-Review of Its Anti-Biofilm and Antimicrobial Effects.","authors":"Samane Teymouri, Maryam Pourhajibagher, Abbas Bahador","doi":"10.2174/0118715265329198241105030008","DOIUrl":"https://doi.org/10.2174/0118715265329198241105030008","url":null,"abstract":"<p><p>The resistance of biofilms to antimicrobial agents presents numerous challenges. The formation of biofilms leads to enhanced resistance to adverse environmental condi-tions, as well as to antimicrobial agents. Natural compounds have been of interest as po-tential therapeutic agents. Emodin, a natural anthraquinone compound, has recently at-tracted attention for its potential as a broad-spectrum antimicrobial agent. This ability could potentially help combat biofilm-associated infections and enhance the effectiveness of an-timicrobial therapies. This review was carried out to evaluate the effects of emodin on mi-crobial biofilms, determine its effectiveness in inhibiting and reducing biofilm formation, eradicate biofilms, and examine its antimicrobial effects. Our study shows that the use of emodin as an additional therapeutic agent in combating microbial biofilms holds consider-able promise. As researchers continue to investigate how emodin interacts with microbial biofilms, there is excitement about the potential applications of this natural compound in addressing biofilm-related issues. However, it is suggested to pay more attention to evalu-ating the effects of emodin on microbial biofilms in future studies.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Study of Intradural Extramedullary Spinal Schwannoma and Multiple Thoracic Vertebral Haemangiomas Following COVID-19 Infection and Vaccination: Insights from MRI Imaging.","authors":"Naif Ali A Majrashi","doi":"10.2174/0118715265313930241022102849","DOIUrl":"10.2174/0118715265313930241022102849","url":null,"abstract":"<p><strong>Introduction: </strong>Spinal schwannomas are benign intradural extramedullary tumors of Schwann cells, while hemangiomas are common benign vascular tumors found in the vertebral column.</p><p><strong>Case representation: </strong>This case study presents a 32-year-old male who developed both a spinal schwannoma and multiple thoracic vertebral haemangiomas following a COVID-19 infection and subsequent vaccination. The patient reported intermittent lumbar and thigh pain over 6-8 months. Magnetic resonance imaging (MRI) confirmed an intradural ex-tramedullary schwannoma at the L5 vertebra and multiple thoracic haemangiomas at the T6-T7 levels. The schwannoma was surgically resected, and pathology confirmed the di-agnosis. Postoperatively, the patient's symptoms improved significantly, with no compli-cations.</p><p><strong>Conclusion: </strong>This case raises questions about a possible link between COVID-19 and these spinal conditions. Further research is warranted to explore the potential association between viral infection, vaccination, and tumor development.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}